{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:05Z","timestamp":1787841005241,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Bristol-Myers Squibb Co Summit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.semarthrit.2023.152240","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T20:35:29Z","timestamp":1688157329000},"page":"152240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-0715","authenticated-orcid":false,"given":"Teresa A","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"Skovron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleb","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frisell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Dominique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152240_bib0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0002","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0003","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0004","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0005","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0006","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0007","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"Schiff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0008","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0010","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0011","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3899\/jrheum.080813","article-title":"Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study","volume":"36","author":"Westhovens","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0012","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3899\/jrheum.111531","article-title":"Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy","volume":"39","author":"Genovese","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0013","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/ard.2010.139345","article-title":"Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial","volume":"70","author":"Kremer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0014","unstructured":"Bristol Myers Squibb. Orencia (abatacept) prescribing information. 2019. http:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf (accessed 28 August 2019)."},{"key":"10.1016\/j.semarthrit.2023.152240_bib0015","unstructured":"Orencia 250\u00a0mg powder for concentrate for solution for infusion 2017 [Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/19714\/SPC\/ accessed 21 May 2018."},{"key":"10.1016\/j.semarthrit.2023.152240_bib0016","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0017","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0018","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0019","doi-asserted-by":"crossref","first-page":"22279","DOI":"10.3390\/ijms151222279","article-title":"Smoking and rheumatoid arthritis","volume":"15","author":"Chang","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0020","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0021","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidermiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0023","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0024","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0025","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0026","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0027","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","article-title":"The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"55","author":"Silva-Fernandez","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0028","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF alpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.120906","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0031","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","article-title":"Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment","volume":"66","author":"Alten","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0032","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/acr2.1034","article-title":"Safety of abatacept versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials","volume":"1","author":"Simon","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0033","unstructured":"International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). 2015. https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/ (accessed July 1, 2020)."},{"key":"10.1016\/j.semarthrit.2023.152240_bib0034","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trial"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0035","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","article-title":"Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0036","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/art.40017","article-title":"Rheumatoid Arthritis and Risk of Malignant Lymphoma: is the Risk Still Increased?","volume":"69","author":"Hellgren","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152240_bib0037","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/annrheumdis-2017-212395","article-title":"Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics","volume":"77","author":"Frisell","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:12:57Z","timestamp":1758733977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":37,"alternative-id":["S0049017223000823"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152240","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152240"}}